Scienjoy Revenue Falls to 305.4 Million Yuan as Medifast Cuts Outlook
Key Facts
Scienjoy revenue fell to 305.4 million yuan in the second quarter ended June 30, 2026, from 349.0 million yuan in the same period a year earlier, according to unaudited financial results released by the company via PR Newswire. In the same quarter, Medifast reported revenue of 76.4 million dollars, down 27.6% from 105.6 million dollars in the second quarter of 2025, according to its filing with the U.S. Securities and Exchange Commission. Both companies therefore reported year-over-year revenue declines in the second quarter, although the available data do not provide comparable details on the reasons for Scienjoy's revenue decline. Medifast's figures show that the revenue drop coincided with a contraction in its network of active earning coaches. The companies' shares closed on October 23 at 11.87 dollars for Medifast and 0.85 dollars for Scienjoy, according to EL7's daily closing data.
Medifast said the number of active earning coaches fell 48.7% to 11,700 in the second quarter, from 22,800 in the same period of 2025. The company attributed the contraction mainly to continued pressure on customer acquisition amid broader challenges in the operating environment. It added that the rapid spread of GLP-1 weight-loss drugs was among the factors affecting this trend. By contrast, average revenue per active earning coach rose to 6,529 dollars, compared with 4,630 dollars a year earlier, an increase of 41.0%. The company linked the improvement to prioritizing more productive coaches and improving the structure of its network, lifting average revenue per coach despite their lower number.
In its second-quarter filing, Chief Executive Nick Johnson said revenue remained stable sequentially, supported by steady growth in coach productivity and positive trends among network leaders. He added that, alongside those indicators, the energy and engagement coaches showed at the company's latest national convention had historically preceded subsequent growth. The message reflects management's focus on coach network productivity and engagement indicators, while the number of active coaches remained well below its level a year earlier. In August, the company had forecast third-quarter 2026 revenue of between 60 and 80 million dollars. It also forecast a loss per share of between 0.15 and 0.65 dollars, excluding nonrecurring costs related to implementing the Catalyst initiatives.
For the full year, Medifast set a 2026 revenue range of between 270 and 300 million dollars in August. The estimates come amid the second-quarter year-over-year revenue decline and a drop in the number of active coaches, alongside an increase in average revenue per coach. The company ties customer acquisition pressures to the operating environment and the spread of weight-loss drugs, while pointing to coach productivity and engagement indicators as supporting factors. For Scienjoy, the figures cited are limited to a quarterly revenue decline to 305.4 million yuan from 349.0 million yuan a year earlier, with no additional data here on drivers or forecasts for coming periods. Medifast's third-quarter and full-year forecasts were issued in August and include quarterly and annual revenue ranges and an estimate for third-quarter loss per share.